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Although half of all children with neuroblastoma will be cured of
their disease, there are still subgroups in whom the outlook
remains poor. These include children with metastatic disease,
particularly affecting bone, or those with regional disease in whom
the tumour shows N-MYC amplification or chromosome 1p dele-
tion. In these patients, despite intensive multiagent chemotherapy
often followed by high dose chemotherapy with stem cell rescue,
less than one-quarter will be long-term survivors. Since the intro-
duction of cisplatin–etoposide combinations there have been few
new chemotherapy agents which have proven to be active in
neuroblastoma. Alternative strategies, such as dose escalation or
high dose intensity regimens, may have improved remission rates
but have had only modest impact on cure rates. There is therefore
an urgent need for new approaches in this disease.
As in other childhood tumours, drug resistance in neuroblas-
toma is multifactorial, but there is evidence that multidrug resis-
tance (MDR) involving P-glycoprotein (P-gp), the product of the
MDR1 gene or MDR-related protein, the product of the MRP gene
may influence both the biological behaviour of these tumours and
response to chemotherapy (Bourhis et al, 1989; Chan et al, 1991;
Bordow et al, 1994; Norris et al, 1996). Resistance to several of
the most important drugs used in children’s cancer, for example
anthracyclines, vincristine, etoposide and actinomycin, has been
shown to involve these mechanisms.
Modulation of P-gp function has been demonstrated in a range of
tumour cell lines using a variety of compounds. The most exten-
sively evaluated in clinical practice are verapamil and cyclosporin A
(Cairo et al, 1989; Lum et al, 1993; Cowie et al, 1994, 1995; Chan
et al, 1995). The cyclosporin analogue PSC 833 has been introduced
more recently (Helson et al, 1994; Boote et al, 1996) and is currently
undergoing a dose-finding study in children. The major drawback of
MDR modulation strategies thus far has been the unacceptable level
of toxicity of the modulating agent. In the case of verapamil, it has
proven difficult to achieve blood drug levels in patients comparable
to those shown to be effective in vitro due to cardiac toxicity.
Similarly, with high dose cyclosporin, dose-limiting nephrotoxicity
and hepatic toxicity have compounded the extramedullary toxicity
of the cytotoxic chemotherapy. There is, therefore, a need for alter-
native reversal agents with a lesser toxicity to normal tissue.
VX-710 is a non-macrocyclic pipecolinate derivative which
binds the FK506 receptor protein. VX-710 has been shown to
restore sensitivity in a range of multidrug-resistant cells, including
myeloma, melanoma, carcinoma and leukaemia (Germann et al,
1997a). The drug inhibits the efflux activity of P-gp and stimulates
vanadate-sensitive P-gp ATPase activity, suggesting a direct high
affinity interaction between VX-710 and P-gp (Germann et al,
1997a). Of particular importance are results from Phase I clinical
studies in adults which have shown this agent to have an encour-
aging toxicity profile with doses up to 120 mg m–2 per hour as a 24
to 96-h infusion. Minimal adverse reactions. These included
headaches, mild to moderate nausea and mild reversible hypoten-
sion. At the highest dose there was mild hyperbilirubinaemia
(Rowinsky et al, 1998). Steady-state concentrations of VX-710 (³8
mM) were 2–3 fold higher than level effective in vitro as an MDR
modulator. Moreover, hepatic retention of sestamibi increased up to
eightfold during VX-710 administration, suggesting inhibition of
P-gp in the liver (Peck et al, 1995).
In the present study, a range of neuroblastoma cell lines have
been characterized with regard to drug resistance phenotype and
the chemosensitization to several cytotoxic agents using PSC 833,
cyclosporin and VX-710. Three methods were used: microtitre
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Summary Clinical studies have suggested that both MDR1 and MRP may play a significant role in the chemosensitivity and outcome of
neuroblastoma. To clarify the nature of multidrug resistance (MDR) in this tumour a series of six neuroblastoma cell lines have been
characterized with regard to P-glycoprotein, MRP and LRP expression using immunocytochemistry and expression of MDR1, MRP, LRP and
topoisomerase II genes using reverse transcription polymerase chain reaction (RT-PCR). By RT-PCR, all lines expressed MRP, five
expressed LRP and four expressed MDR1, but protein levels of each of these were variable. Chemosensitization to a range of
MDR-associated drugs (vincristine, doxorubicin, etoposide, taxotere, topotecan) and non-MDR-associated drugs (cisplatin, melphalan) by
three modulating agents, cyclosporin A, PSC 833 and the novel Biricodar (VX-710; Incel™), was evaluated using a colourimetric cytotoxicity
assay (MTS). Alteration of daunorubicin efflux by these agents was evaluated using FACS analysis. Clonogenic assay was used to study the
influence of these chemosensitizers on vincristine cytotoxicity. Marked sensitization to vincristine was observed in MDR1-positive lines, and a
similar but less consistent effect was seen with taxotere, doxorubicin and etoposide. With MRP-positive, MDR-negative lines, only VX-710
caused consistent sensitization. These data confirm MDR1 and MRP expression as contributory factors in chemoresistance in neuroblastoma
and indicate that VX-710 may be a useful modulator of both mechanisms and worthy of clinical evaluation in this tumour.
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tetrazolium–formazan assay (MTS), clonogenic assay and
daunorubicin efflux with FACS.
METHODS
Cell lines and culture conditions
The derivation and characterization of the six established human
neuroblastoma cell lines used in this study are outlined in Table 1.
SKNBE, IMR-32, SKNSH and SKNBE cells were obtained from
the American Tissue Culture Collection (Rockville, MD, USA).
NB-1 cells were obtained from the Japanese Cancer Research
Resources Bank (Tokyo, Japan). Hx-138 and Hx-142 were
provided by Professor G Steele (Radiotherapy Unit, Institute of
Cancer Research, Sutton, UK) (Tumilowicz et al, 1970; Biedler
et al, 1973; Inui, 1974; Biedler and Spengler, 1976; Deacon, 1986;
Hills et al, 1989; Feller et al, 1995). The doxorubicin-resistant,
non-small-cell lung cancer cell line, 2R120, was used as a positive
control for MRP expression and provided a negative control for
P-gp. The sensitive human ovarian carcinoma line CH-1 and the
doxorubicin-resistant derivative line CH-1R were used as negative
and positive controls for MDR-1 expression. Cell lines were main-
tained as monolayers and incubated at 37°C in a humidified
atmosphere with 5% carbon dioxide in culture media supple-
mented with 10% heat-inactivated fetal bovine serum (FBS;
GibcoBRL, UK), 1 ml 100 ml–1 Glutamax (Gibco), 100 U ml–1 of
penicillin and 100 mg ml–1 streptomycin. RPMI-1640 medium
(Gibco) was used for SKNBE, SKNSH, IMR-32 and NB-1, Ham’s
F12 (Gibco) for HX-138 and HX-142, and DMEM (Gibco) for all
control cell lines. Maintenance doses of doxorubicin were used to
retain the MDR phenotype of the drug-resistant cell lines until at
least 48 h before the start of experiments. All cell lines were
routinely screened for mycoplasma by PCR assay (Mycoplasma
Primer Set, Stratagene, Cambridge, UK).
MDR characterization by immunocytochemistry
The consensus recommendations of the multicentre workshop
were applied, where possible, in this study (Beck et al, 1996). Two
antibodies raised against spatially distinct segments of each
protein were used for the immunocytochemical detection and
semi-quantitative measurement of MRP and P-gp. Control reac-
tions used appropriately matched isotypes or no primary antibody.
Cytospin preparations of 50 000 cells were fixed in acetone at
–20°C for 5 min, air-dried, preincubated in 10% human AB serum
in phosphate-buttered saline (PBS) A, followed by incubation with
the primary antibody for 1 h. For detection of P-gp, the mouse
monoclonal antibodies, MRK 16 (TCS Biologicals Ltd, Boltolph
Claydon, UK), 1:25 dilution, JSB –1, 1:10 and for MRP the anti-
bodies MRPr1, raised in rat (Sigma Chemicals, Poole, UK), dilu-
tion 1:50 and MRPm6 (kindly provided by Dr Rik Scheper, Free
University, Amsterdam, The Netherlands) raised in mouse at 1:25
were used. The second antibody, rabbit anti-mouse or anti-rat
(Dako, Glastrup, Denmark) was used at 1:50 dilution for 30 min.
A standard APAAP technique (DAKO) was used for colourimetric
development with levamisole (Sigma) to block activity of endoge-
nous alkaline phosphatase. All incubations were at room tempera-
ture. Slides were counterstained with Mayer’s haematoxylin
(Sigma, 2 min). Cells were graded as negative when no staining
was apparent and from (+) to (++++), according to the intensity of
staining (Beck et al, 1996). Positive control cell lines scored (+++)
or (++++) for MRP and P-gp. Reproducibility of the results was
confirmed in each case by two repeat experiments.
Reverse transcriptase polymerase chain reaction
Oligonucleotides All sequences of polymerase chain reaction
(PCR) primers were as previously reported. Reverse transcription
(RT)-PCR analysis of MDR1 and MRP gene expression was
performed using two non-overlapping primer pairs, which gave
concordant results for each gene in all cell lines (MDR-1: 401-bp
product (Futscher et al, 1993); 157-bp product (Bordow et al, 1994);
MRP: 565-bp product (Beketic-Oreskovic et al, 1995);
140-bp product (Bordow et al, 1994)). Other primer sets were:
topoisomerase II a (topo II a), 322-bp product (Beck et al, 1995),
topoisomerase II b (topo II b), 304-bp (Beck et al, 1995),
lung-related resistance protein (LRP), 405-bp (Stein et al, 1997),
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 358-bp and
b2 microglobulin (b2M), 120-bp (Bordow et al, 1994). All primer
sets spanned an intron to control against amplification of genomic
DNA sequences. Two internal controls (GAPDH and b2M) were
used to assess the quality of template in each reaction. All primers
were purchased from Oswel DNA Service Lab (Southampton, UK).
Total RNA (1 mg) was reverse transcribed in a 20 ml volume
using Superscript II (GibcoBRL) and random hexanucleotides
(Pharmacia), according to the manufacturers’ instructions. PCR
was performed on 50 ng of cDNA in a final volume of 50 ml
containing 25 pmol of each primer, 0.4 mM dNTPs (Pharmacia),
20 mM Tris–HCl, 50 mM potassium chloride, 1.8 mM magnesium
chloride and 2.5 U ml–1 of Taq DNA polymerase (Gibco BRL). An
initial denaturation for 4 min at 94°C was followed by 27–35
cycles of 45 s at 94°C, 45 s at 55°C, 90 s at 72°C in an Omnigene
Table 1 Clinical data on origins of the neuroblastoma cell lines
Cell line Patient age Tissue source Prior therapy Response to therapy
(months)
SKNBE 24 Bone marrow RT, VCR, CTX, ADR, ACT None
SKNSH 48 Bone marrow RT, VCR, CTX, DNR, FMdU, ADR None
HX-142 19 Primary tumour VCR, CDDP, VM-26, CTX PR
HX-138 72 Primary tumour RT, VCR, CDDP, ETOP, CTX PR
NB-1 33 Cervical lymph node RT, ACT, CTX, VCR PR
IMR32 13 Primary tumour None
RT = radiotherapy (specimens were not obtained from within the radiation port); VCR = vincristine; CTX = cyclophosphamide; ADR = doxorubicin;
ACT = dactinomycin; DNR = daunomycin; FMdU = trifluoromethyl-2¢-deoxyuridine; CDDP = cisplatin; VM-26 = teniposide; ETOP = etoposide;
DTIC = dacarbazine; PR = partial response.1192 T Yanagisawa et al
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thermal cycler (Hybaid, UK). PCR products (20 ml) were visual-
ized by gel electrophoresis (2% agarose or 12% polyacrylamide)
and ethidium bromide staining. Each sample was assayed at least
twice and scored as positive if the correct sized PCR product was
detected in two or more experiments with appropriate negative
controls (no RNA, no DNA).
Chemicals
Drug sources were as follows: vincristine (Farmitalia Carlo Erba
Ltd, Herts, UK), doxorubicin (Eli Lilly, Basingstoke, UK),
melphalan and etoposide (Sigma, UK), cisplatin (Johnson
Matthey, Reading, UK), taxotere (Rhone-Poulenc, France),
topotecan (SmithKline Beecham Pharmaceuticals, Herts, UK),
cyclosporin A and PSC 833 (Novartis Pharmaceuticals,
Camberley, UK), VX-710 (Vertex Pharmaceuticals Inc.,
Cambridge, MA, USA). Stock solutions were prepared in saline or
water with the exception of: (1) melphalan, which was solubilized
in a minimum quantity of 4.5% ethanolic hydrochloric acid and
then diluted at least 50-fold in medium before addition to cultures;
(2) etoposide and PSC 833, which were solubilized in absolute
alcohol and similarly diluted; (3) VX-710 was diluted in the
diluent DMEM. Stock solutions were diluted with tissue culture
media just before use. The levels of the diluted solvents alone
showed no toxic effect on cells (data not shown).
Functional analysis of P-gp and MRP
Cells in single cell suspension (0.5–1.0 ´ 106 in 1 ml aliquots)
were equilibrated for 30–60 min at 37°C in the absence/presence
of modulating agents (PSC 833 500 nM, VX-710 5 mM) in
Dulbecco’s phenol-red free medium with 10% FCS. Daunorubicin
(Sigma Chemicals), at a concentration of 5 mM was then added,
with a further 60 min incubation. Following the fluorescent probe
accumulation phase, cells were pelleted by centrifugation at
2000 g, 4°C, and resuspended in fresh medium, again in the
absence or presence of the appropriate modulating agent. Cells
were allowed to efflux for a further 60 min at 37°C and were then
pelleted as before. Following resuspension in drug-free medium,
cells were stored on ice prior to analysis. Throughout the incuba-
tion periods, cells were gently agitated at regular intervals to
prevent excessive clumping. A control untreated cell suspension
was run at the beginning of each analysis, to allow elimination of
clumped cells and debris by gating out. Fluorescence was analysed
for 10 000 events using a Coulter Epics ESP Elite flow cytometer.
Cytotoxicity assays
The drug sensitivity and the potencies of the modulators were
determined by the MTS cytotoxicity assay (Promega) for all cell
lines and clonogenic assay in SKNBE (Goodwin et al, 1995). Cells
were seeded at 2500–5000 cells per well to allow exponential
growth over not more than four doublings during the incubation
period. Plates were preincubated for 24 h, then cytotoxic drugs
with or without modulator were added to a final volume of 200 ml.
Modulators were used at a concentration that produced less than
10% cell death (PSC833 and cyclosporin A were used at 0.5 mM
for all lines; VX710 was used at 5 mM for all lines except HX138
(2.0 mM) and NB-1 (1.0 mM)). Control wells contained medium
only or cells alone. All experimental points were set up in quad-
ruplicate wells and all experiments were repeated at least three
times. The MTS assay was performed after 72–156 h, depending
on the doubling time, to obtain an IC50 for each drug. The resis-
tance modifying factor or sensitization ratio was calculated as
(IC50 with drug alone)/(IC50 drug + modulator).
Clonogenic assays were performed using a modification of Pike
and Robinson’s double layer agar technique (Pike and Robinson,
1970). Five hundred neuroblastoma cells were plated in the pres-
ence of 0.0001, 0.001, 0.01 and 1.0 mM vincristine alone or with
modulator (0.5 mM cyclosporin A or PSC 833, 5.0 mM VX-710).
Cell suspensions were prepared by trypsinization of monolayers
and gently passing through a 21-gauge needle. The effectiveness
of this procedure to achieve a suspension of single cells was
checked microscopically. Each drug concentration and modulator
combination was set up in triplicate. Plates were incubated for 14
days. Aggregates of more than 50 cells were scored as colonies.
Survival was expressed as a percentage of control colony counts.
The nonparametric, two-sided Mann–Whitney rank sum test
was used to analyse the MTS assay data, comparing median sensi-
tization ratios from at least three independent experiments for each
data point. Statistical significance was established on the basis of
95% confidence intervals.
RESULTS
MDR expression
Expression of three genes implicated in multidrug resistance
(MDR-1, MRP, LRP) was assayed at both the mRNA and protein
level in six neuroblastoma and three control cell lines (Table 2).
Topoisomerase II a or b were assayed solely by RT-PCR.
Table 2 Expression of MDR-related genes in neuroblastoma and control cell lines
Immunocytochemistry staining RT-PCR
Cell line MDR-1 MRP LRP MDR-1 MRP LRP
MRK16 JSB-1 MRP-6 m MRPr-1 LRP-56
SKNBE (+++) (+++) (+) (+++) (–) + + +
SKNSH (+++) (+++) (+) (+++) (–) + + +
HX142 (+) (+) (++) (+++) (–) + + –
HX138 (+) (+) (+) (++++) (+++) + + +
NB1 (++) (++) (+) (+) (–) – + +
IMR 32 (–) (–) (–) (–) (–) – + +
CH-1P (–) (–) (–) (–) (–) – + +
CH-1R (+++) (++++) (–) (–) (–) + + +
2R120 (–) (–) (+++) (+++) (+++) – + +
Immunocytochemistry – intensity of staining recorded as: negative (–), low (+), intermediate (++), high (+++), ultra high (++++). RT-PCR –
for MDR-1 and MRP two different primer pairs were used. See Methods.VX-710 in neuroblastoma 1193
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P-gp expression was detected in 5/6 neuroblastoma cell lines and
MDR-1 mRNA by RT-PCR in 4/6. NB1 cells gave a discordant
result that was probably due to artefactual binding or cross-reac-
tivity in immunocytochemistry. RT-PCR with two non-overlapping
primer sets was consistently negative and P-gp could not be detected
by either Western or flow cytometric analysis in this cell line (data
not shown). In functional assays, NB1 behaved similarly to IMR32,
which was MDR-1/P-gp negative by all methods.
Five lines (all except IMR32) expressed MRP detectable by
immunohistochemistry. However, all expressed MRP mRNA
detectable by RT-PCR, presumably reflecting the greater sensi-
tivity of the latter technique.
All neuroblastoma lines except one (HX-142) showed expression
of LRP by RT-PCR but mainly at low levels, as only one
(HX-138) had detectable protein by immunohistochemistry. No cell
line showed loss of topoisomerase II a or b expression by RT-PCR.
Table 3 Sensitization of neuroblastoma cell lines to cytotoxic agents by cyclosporin A, PSC 833 and VX710
Cell line Vincristine Taxotere Doxorubicin Etoposide
CsA PSC833 VX710 CsA PSC833 VX710 CsA PSC833 VX710 CsA PSC833 VX710
SKNBE 26 33 61 8.3 8.3 14 2.5 3.1 2.8 2.4 2.2 2.8
SKNSH 6.8 7.4 32 4.7 5.8 7.6 2.4 2.4 3.1 1.3 1.5 1.4
Hx142 6.8 5.3 12 3.3 3.4 3.3 1.8 1.5 2.4 3.3 2.8 3.5
Hx138 5.2 4.6 6.7 5.5 4.1 2.4 2.4 2.0 3.5 2.0 3.5 1.1
NB 1 1.2 1.0 1.6 1.5 0.9 1.2 1.1 0.8 1.8 1.0 1.4 1.0
IMR-32 1.0 0.7 1.5 1.2 1.0 1.0 1.0 0.9 0.9 1.0 1.3 1.4
Data shown are median sensitization ratios (SR) from at least three independent experiments. SR = IC50 with drug/IC50 drug + modulator. IC50 values were
calculated from dose–response curves of MTS cytotoxicity assays. Modulators (cyclosporin A (CsA), PSC 833 (PSC) and VX710 (VX)) were used at
concentrations <IC10 for each cell line.
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Figure 1 Effects of modulators on cytotoxicity of (A) vincristine, (B) taxotere, (C) doxorubicin and (D) etoposide in neuroblastoma cell lines. The results are
presented as the median with the range of IC50 values obtained from at least three independent experiments. Median IC50 values in the presence of modulator
which are statistically significant (non-parametric Mann–Whitney rank sum test, P < 0.05) from those for the drug alone are asterisked. n n, Drug; alone,  ,
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Reversibility of drug resistance by MDR modulators
The ability of the three modulators, cyclosporin A, PSC 833 and
VX-710, to overcome resistance to a panel of drugs, was examined
in all cell lines by an MTS assay. The drug panel included five
drugs derived from natural products which are expected to be
transported by P-gp (vincristine, doxorubicin, etoposide, taxotere
and topotecan) and two drugs (melphalan and cisplatin) which are
not. All of these drugs, with the exception of taxotere and
topotecan, are commonly used in the treatment of neuroblastoma.
In the MTS assay, modulation values were expressed as a sensiti-
zation ratio (SR): (IC50 drug alone)/(IC50 drug + modulator) (Table
3). Examples of histograms of median IC50 are illustrated for the
four drugs for which statistically significant modulation was
detected in the neuroblastoma cell lines (Figure 1 A–D).
The degree of modulation was most marked with vincristine (up
to 61-fold) and for VX710 often exceeded the level seen in the
MDR-1 positive control cell line, CH-1R. No modulation of IC50
was seen in the sensitive control cell line, CH1-P. Modulation of
sensitivity to etoposide, doxorubicin and taxotere was variable and
generally much less marked (up to 14-fold) than with vincristine.
Of interest, no modulation of topotecan sensitivity was seen,
although previous studies have demonstrated that topotecan can be
transported by P-gp (Hendriks et al, 1992). No modulation was
seen in any line with melphalan or cisplatin (Table 3 and data not
shown).
The relative efficacy of the three modulators in reversing drug
resistance was variable. VX-710 was generally the most effective
modulator in the neuroblastoma cell lines, whereas PSC833 gave
superior modulation in the two positive control cell lines. Both
were generally superior to cyclosporin A.
Correlation of modulation of drug resistance with P-gp
and MRP expression
No cell line was completely ‘clean’ in having only one possible
mechanism of drug resistance. Such multiplicity of mechanisms is
probably common in vivo as well as in vitro and makes simple
correlations impossible. All three modulators sensitized both the
P-gp- and MRP-positive control cell lines to doxorubicin. The
extremely high level of vincristine resistance in the MRP-positive
control line 2R120 was not influenced by the modulators,
implying additional resistance mechanisms for this drug in this cell
line. VX710 gave the greatest number of significant modulations
Table 4 Functional assay of effect of modulators on daunorubicin efflux
Cell line Efflux ratio
PSC 833 VX710
SKNBE 1.5 1.1
(0.21) (0.14)
SKNSH 1.2 1.3
(0.19) (0.19)
Hx142 2.4 2.2
Hx138 1.3 1.2
NB1 1.4 1.2
(0.16) (0.06)
IMR32 1.2 1.3
(0.10) (0.16)
CH-1 Pa 1.0 1.0
CH-1 Re 6.2 6.0
(0.58) (0.79)
2R120 1.6 1.7
(0.26) (0.11)
Efflux ratio = daunorubicin fluorescence in the presence of
modulator/daunorubicin fluorescence alone. Data points are either the mean
of three or more experiments with standard deviation in parentheses or the
mean of two experiments.
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Figure 2 Survival of clonogenic SKNBE neuroblasts exposed to vincristine
alone or in combination with modulators. –• •– without modulator, –•– with
modulator (A = 0.5 mm CSA, B = 0.5 mm, PSC 833, C = 5 mm VX710)VX-710 in neuroblastoma 1195
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across the drug panel. In the four neuroblastoma cell lines with
both P-gp and MRP expression, VX-710 was the only modulator
to significantly sensitize two lines to etoposide and one line to
taxotere. VX710 was the only modulator to show an effect in line
NB-1, whose drug resistance was ascribed to MRP rather than
P-gp (SR = 1.6 for vincristine and 1.8 for doxorubicin).
Clonogenic and functional assays
A subset of modulators and cell lines was further examined by two
complementary assays: a clonogenic assay to assess modulation of
cytotoxicity on clonogenic cells and a functional assay of drug
efflux. The clonogenic assay was only performed for SKNBE
exposed to vincristine in combination with each of the three modu-
lators (Figure 2). These results show that all three modulators
enhance the killing of clonogenic cells in addition to the overall
enhancement of cytotoxicity demonstrated by the MTS assays.
Using the functional assay, retention of daunorubicin was clearly
enhanced in the CH-1R Pgp-positive control line by both PSC833
and VX-710 (Table 4). This assay showed a more modest degree
of modulation in the neuroblastoma cell lines and the MRP-
positive control for both VX-710 and PSC 833.
DISCUSSION
This study characterized the MDR phenotype of a range of
neuroblastoma cell lines and documented the activity of VX-710
as a drug resistance modulator compared to cyclosporin A and
PSC 833. The secondary objective was to determine to what extent
any sensitization was linked with known mechanisms of MDR.
As expected from the discussions of the multicentre workshop
(Beck et al, 1996) there was some discordance between the
characterization of cell lines using different methods. In general,
there was a high level of concordance between RT-PCR and
immunocytochemistry for both MDR1 and MRP. The staining
intensity for both MDR1 and MRP varied depending on the anti-
body used (Table 2). Discordance occurred only in the case of
NB-1 where gene expression was not apparent on RT-PCR despite
apparent immunoreactivity. The lack of modulation with
cyclosporin A and PSC 833 together with the observation that no
significant P-gp levels were detected by either Western of FACS
analysis implies that the immunocytochemical staining was a false
positive. Functionally significant MRP expression appeared to
correlate with positivity in immunocytochemistry rather than
RT-PCR. IMR32 and CH-1P were only MRP-positive by RT-PCR
and showed no evidence of modulation. All neuroblastoma cell
lines expressed the LRP gene but most did not have detectable
protein. In no cell line was there evidence of complete absence of
topoisomerase II expression by RT-PCR, although a reduction in
level of expression would not be detected by this method.
Cytotoxicity and modulation was evaluated using three inde-
pendent methods, MTS, clonogenic assay and drug efflux modula-
tion. The commonly used MTS or MTT assays have the limitation
of assessing overall cell kill, not necessarily cells capable of
repopulation. In this study there was close correlation between the
modulation observed with all three modulators as evaluated by
either MTS or clonogenic assay. Efflux assay using either
daunorubicin or rhodamine may shed light on the mechanism by
which VX-710 influences cytotoxicity. It is clear, however, that
changes in drug efflux are not necessarily translated into cell kill.
The degree of sensitization to anthracyclines using VX-710 or
PSC 833 were more marked with MTS assay than might have been
predicted with functional assay, particularly in SKNBE and HX138.
A close correlation between cytotoxicity as measured by MTS assay
and drug efflux was apparent for the P-gp control cell lines. The
sensitive parental line, CH1-P, showed no evidence of modulation
whereas in the resistant line, CH-1R, marked enhancement of drug
retention was reflected in high levels of cytotoxicity to both
vincristine and doxorubicin. In clinical practice, the functional assay
is generally the method of choice for evaluating leukaemia, where
fresh tumour cells can be readily evaluated. For solid tumours this is
difficult and the MTS assay may be more practical.
In the present study the highest dose used for the VX-710 studies
was 5 mM. This is a concentration which is readily achieved in clin-
ical studies (Rowinsky et al, 1998). Even lower concentrations may
be effective as dose–response studies (data not shown) failed to
show any significant difference in the modulation of SKNBE with
vincristine over a VX-710 concentration range of 0.5–5 mM.
VX-710 functions in a similar way to the modulators
cyclosporin A and PSC 833, influencing the drug accumulation
defect by direct interaction with P-g as indicated by photoaffinity
labelling experiments. Further evidence of direct high affinity
interaction between VX-710 and P-gp is found in the concentra-
tion-dependent stimulation of P-gp ATPase activity. The concen-
trations of VX-710 required to reverse MDR in vitro in a range of
cell lines assessed using rhodamine, sestamibi and labelled
doxorubicin are similar to cyclosporin A (Germann et al, 1997a,
1997b). It is unclear to what extent the compound acts as a
competitive ligand for binding sites of cytotoxics.
The main attraction of VX-710 in clinical practice is its striking
lack of organ toxicity. Other agents active in vitro such as
verapamil and high-dose cyclosporin are significantly limited in
clinical use, particularly with combination chemotherapy. Both have
inherent toxicity and alter chemotherapy pharmacokinetics. Dose-
finding studies in adults have demonstrated that the maximum toler-
ated dose of VX-710 is well in excess of that required to achieve
drug levels found to effectively influence drug efflux in vitro.
Moreover, preliminary studies in vivo using sestamibi have shown
that VX-710 will enhance both hepatic and tumour retention of this
surrogate marker for P-gp-related drugs (Peck et al, 1995).
In conclusion, it is apparent that in a range of neuroblastoma
cell lines, both VX-710 and PSC 833 are effective sensitizers of
MDR-modulated chemotherapy. Although this sensitization is
predominantly P-gp-dependent, VX710 did appear to have a
broader spectrum of modulator activity. In the two MDR-1-
negative lines, which were both MRP-positive, there was some
evidence of sensitization using VX-710, which was not apparent
with PSC 833 or cyclosporin A. In the MRP control line 2R120,
VX-710 was as effective as the other agents in sensitizing to
doxorubicin. This is an indication for extension of dose-finding
studies in adults to children with refractory or recurrent neuro-
blastoma or other solid tumours known to be P-gp-positive.
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